TargetMol

Peimine

Product Code:
 
TAR-T6S0107
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6S0107-5mg5mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6S0107-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6S0107-10mg10mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6S0107-25mg25mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6S0107-50mg50mg£250.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6S0107-100mg100mg£357.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
1. Peimine has good anti-inflammatory effects in vivo. 2. Peimine is an inhibitor to inhibit LPS-induced production of inflammatory cytokines by blocking the MAPKs and NF-κB signaling pathway.
CAS:
23496-41-5
Formula:
C27H45NO3
Molecular Weight:
431.661
Purity:
0.9995
SMILES:
[H][C@@]12CC[C@@]3([H])[C@@]([H])(CN4C[C@@H](C)CC[C@@]4([H])[C@@]3(C)O)[C@]1([H])C[C@@]1([H])[C@@]2([H])C[C@H](O)[C@@]2([H])C[C@@H](O)CC[C@]12C

References

Yi P F , Wu Y C , Dong H B , et al. Peimine impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-?B and MAPK in LPS-induced RAW264.7 macrophages[J]. Journal of Immunopharmacology, 2013, 35(5):6.